 |
 |
 |
 |
 |
 |
Treatment Name: |
 |
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
|
 |
 |
 |
 |
Phase: |
 |
Phase 1 |
 |
 |
 |
 |
 |
 |
Treatment ID#: |
 |
1892 |
 |
 |
 |
 |
Age Group: |
 |
Adults Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
Not Specified |
 |
 |
 |
 |
Conditions: |
 |
Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Inclusion Criteria:
Previous diagnosis of GBM treated with radiotherapy with or without surgical resection and/or chemotherapy
Clinical/radiographic suspicion of tumor recurrence/progression
Exclusion Criteria:
Previous treatment of target GBM with stereotactic radiosurgery, brachytherapy, or carmustine impregnated wafers (Gliadel).
|
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
11/19/2008 |
 |
 |
 |
 |
Tumor Types: |
 |
Glioblastoma Multiforme |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
For questions or help getting into the trial, contact:
Laura Knapp, Director of Clinical Trials
clinicaltrial@monteris.com
|
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Surgery |
 |
 |
 |
 |
Contact: |
 |
Andrew Sloan M.D. University Hospital – Case Medical Center Contact: Christopher Murphy RN;
Cleveland, OH 44106 USA Phone: 216-983-0796 Fax: E-mail: christopher.murphy@uhhospitals.org Website: |
 |
 |
- Last updated refers to the date when our listing for each treatment was last updated.
- ID is a combination of our internal ID and the official ID for the trial, if any.
- Min Karnofsky is a general guide to how well you have to function to use this treatment
|
|